ONO-7436 [aprepitant] phase II study − A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to examine the efficacy and safety of ONO-7436 for the prevention of cancer chemotherapy-induced nausea and vomiting in Japan.
Latest Information Update: 19 Jun 2012
Price :
$35 *
At a glance
- Drugs Aprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 13 Nov 2005 New trial record.